TAG
FDA approval
Ultomiris wins FDA approval for IgA nephropathy
Ultomiris has won FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy, based on a 43.4% placebo-adjusted cut at week 34.
Enspryng wins FDA approval for thyroid eye disease
Genentech's Enspryng is now the first at-home treatment for thyroid eye disease, after Phase 3 trials showed strong proptosis and double-vision results.
Hibsago approved as first antisense hep B therapy
GSK's Hibsago (bepirovirsen) is the first antisense therapy FDA-approved for chronic hepatitis B, with a 19% functional cure rate in Phase 3 trials.


